Evidence map›Paper›PMID 39769312›Full record

ArticleInternational journal of molecular sciences2024

Molecular Subgroups of HRD Positive Ovarian Cancer and Their Prognostic Significance.

Tatiana Kekeeva, Irina Dudina, Yulia Andreeva, Alexander Tanas, Alexey Kalinkin, Victoria Musatova, Natalia Chernorubashkina, Svetlana Khokhlova, Tatiana Tikhomirova, Mikhail Volkonsky and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Comparison of MR Imaging of High-grade Serous Carcinomas with and without Homologous Recombination-deficiency.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tatiana KekeevaLaboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie st., 1, 115522 Moscow, Russia.ORCID 0000-0001-6759-2598
Irina DudinaDay Hospital No. 1, Moscow Municipal Oncological Hospital No. 62, 143515 Moscow, Russia.
Yulia AndreevaDepartment of Pathology, Russian Medical Academy of Continuing Professional Education, 125993 Moscow, Russia.
Alexander TanasLaboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie st., 1, 115522 Moscow, Russia.ORCID 0000-0002-2177-6743
Alexey KalinkinLaboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie st., 1, 115522 Moscow, Russia.ORCID 0000-0001-9215-4581
Victoria MusatovaLaboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie st., 1, 115522 Moscow, Russia.
Natalia ChernorubashkinaDepartment of Surgical Methods of Treatment No. 9, State Budgetary Healthcare Institution Regional Oncological Dispensary, 664035 Irkutsk, Russia.ORCID 0009-0008-1194-4150
Svetlana KhokhlovaOncological Department of Medical Treatment, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after V. I. Kulakov, 117997 Moscow, Russia.ORCID 0000-0002-4597-172X
Tatiana TikhomirovaN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, 115522 Moscow, Russia.
Mikhail VolkonskyDay Hospital No. 1, Moscow Municipal Oncological Hospital No. 62, 143515 Moscow, Russia.
Sergey KutsevLaboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie st., 1, 115522 Moscow, Russia.
Dmitry ZaletaevLaboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie st., 1, 115522 Moscow, Russia.ORCID 0000-0002-9323-2673
Vladimir StrelnikovLaboratory of Epigenetics, Research Centre for Medical Genetics, Moskvorechie st., 1, 115522 Moscow, Russia.ORCID 0000-0001-9283-902X

Funding

Ministry of Science and Higher Education of the Russian Federation RF 193021X0029
6 · The paper itself

Abstract

Homologous recombination repair deficiency (HRD) is involved in the development of high-grade serous ovarian carcinoma (HGSOC) and its elevated sensitivity to platinum-based chemotherapy. To investigate the heterogeneity of the HRD-positive HGSOC we evaluated the HRD status, including BRCA mutations, genomic scar score, and methylation status of

Indexed as

BRCA1 ProteinBRCA2 ProteinDNA MethylationOvarian NeoplasmsAdultAgedAged, 80 and overCystadenocarcinoma, SerousFemaleHumansMiddle AgedMutationPhthalazinesPiperazinesPrognosisRecombinational DNA RepairBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanolaparibPhthalazinesPiperazinesBRCA1 methylationhomologous recombination deficiencyolaparib maintenanceprogression-free survival

Identifiers

PMID39769312
PMCPMC11677867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.